FDA will ensure
that the guidance document associated with this final rule displays
the PRA burden statement toward the beginning of the document.
Inventory as of this Action
Requested
Previously Approved
05/31/2010
36 Months From Approved
1,228
0
0
63,561
0
0
0
0
0
The final rule requires manufacturers
to assess the effect of a manufacturing change on the identy,
strength, quality, purity and potency of a drug as those factors
relate to safety or effectiveness . It addresses changes requiring
submission and approval of a supplement in the following
situations: before the distribution of the drug made using the
change, at least 30 days prior the distribution of the drug,at the
time of distribution of the drug, and changes to be described in an
annual report.
Statute at
Large: 21
Stat. 506 Name of Statute: null
The FDA with this final rule,
amends its regulations on supplements and other changes to approved
NADA and ANADA to implement the manufacturing changes provisions of
the Food and Drug Administration Modernization Act (FDAMA 116), of
1997. These new information collection requirements for this final
rule are program changes (increase), due to agency discretion
caused by changing regulations.
$2
No
No
Uncollected
Uncollected
Uncollected
Uncollected
Saleda Perryman
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.